Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOW-OGESTREL-28 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: ethinyl estradiol and norgestrel inhibit ovulation via suppression of gonadotropins (LH, FSH); increase viscosity of cervical mucus, impairing sperm penetration; alter endometrial structure, reducing implantation likelihood.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Oral contraception
Prevention of pregnancy (FDA-approved)
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 28 days, with 21 active tablets followed by 7 inactive tablets.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norgestrel: ~45 hours (terminal). Ethinyl estradiol: ~13 hours (terminal). Steady-state achieved within 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: metabolized via CYP3A4, undergoes first-pass metabolism, conjugates with sulfate and glucuronide. Norgestrel: primarily metabolized via reduction, hydroxylation, and conjugation; CYP3A4 involved.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal 50-60% as metabolites, fecal 40-50% via biliary elimination. Ethinyl estradiol undergoes enterohepatic recirculation.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norgestrel: 97-99% bound to SHBG and albumin. Ethinyl estradiol: 98% bound to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Norgestrel: 3-4 L/kg (extensive tissue distribution). Ethinyl estradiol: 3-5 L/kg.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Norgestrel: ~90% oral (first-pass metabolism minimal). Ethinyl estradiol: ~45% oral (extensive first-pass metabolism).
Oral: ~70% due to first-pass metabolism.
No dosage adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment (Cr Cl <30 m L/min); use with caution.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in severe hepatic disease or liver tumors (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and monitor liver function; no specific dose adjustment established.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for premenarchal patients. Postmenarchal adolescents: same as adult dose (one tablet daily) after menarche.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for postmenopausal women due to lack of contraceptive need and potential increased risks of thrombosis, cardiovascular events, and malignancies.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day) and is significant in women over 35. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic events (e.g., DVT, PE, stroke, MI); hepatic neoplasia; elevated blood pressure; gallbladder disease; carbohydrate and lipid metabolism effects; headache; uterine bleeding irregularities; ectopic pregnancy risk; reduced efficacy with hepatic impairment; monitoring for hypertension, hyperlipidemia, and glucose intolerance.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders; history of DVT or PE; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; endometrial carcinoma or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels due to CYP3A4 inhibition, but clinical significance is minimal. Maintain consistent dietary habits regarding grapefruit consumption to avoid fluctuation in drug levels. Alcohol does not directly affect efficacy but may impair judgment regarding compliance.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: Low risk of major malformations; no evidence of increased risk of neural tube defects. Second and third trimesters: Possible increased risk of liver tumors and jaundice; may cause fetal harm if administered during pregnancy due to hormonal effects. Post-marketing reports of external genitalia anomalies in male and female fetuses exposed to progestins. Not recommended for use during pregnancy. Discontinue if pregnancy occurs.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk in small amounts; estimated M/P ratio approximately 0.5-0.8 for progestins. May reduce milk production and quality. Use with caution and only if clearly needed. Monitor infant for jaundice, weight gain, and hormonal effects.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dose adjustments recommended in pregnancy as drug is contraindicated. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may reduce efficacy if used inadvertently; discontinue immediately upon recognition of pregnancy.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Low-Ogestrel-28 (norgestrel/ethinyl estradiol) is a monophasic oral contraceptive. Take at the same time daily to maintain hormone levels. Missed pill management: if one pill is missed, take it as soon as remembered; if two or more pills are missed, use backup contraception for 7 days. Consider potential drug interactions with CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) which may reduce efficacy. Breakthrough bleeding is common in first 3 months; if persistent, rule out pregnancy or cervical pathology. Do not use in patients with history of thromboembolic disease, migraines with aura, or smokers >35 years old.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time, even if you do not have intercourse.,If you miss a pill, refer to the packaging instructions or contact your healthcare provider.,Use a backup method (e.g., condoms) during the first week and if doses are missed.,Common side effects include nausea, breast tenderness, breakthrough bleeding, and mood changes; these often improve after 3 months.,Serious risks include blood clots, stroke, and liver tumors; seek medical help for leg pain, chest pain, severe headache, or vision changes.,Do not smoke while taking this medication, especially if over 35 years old.,Inform all healthcare providers that you are taking this contraceptive.,This medication does not protect against HIV or other sexually transmitted infections.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOW-OGESTREL-28 vs AFIRMELLE, answered by our medical review team.
LOW-OGESTREL-28 is a Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol and norgestrel inhibit ovulation via suppression of gonadotropins (LH, FSH); increase viscosity of cervical mucus, impairing sperm penetration; alter endometrial structure, reducing implantation likelihood.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOW-OGESTREL-28 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOW-OGESTREL-28 is: One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 28 days, with 21 active tablets followed by 7 inactive tablets.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOW-OGESTREL-28 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOW-OGESTREL-28 is classified as Category C. First trimester: Low risk of major malformations; no evidence of increased risk of neural tube defects. Second and third trimesters: Possible increased risk of liver tumors and jau. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.